Skip to content

Potential Beneficial Effects of Resveratrol

Potential Beneficial Effects of Resveratrol on Obesity, Metabolic Syndrome and Inflammation - Emphasis on Description of the Molecular Biology Underpinning the Interplay Between Calorie Restriction, SIRT1, STAT5 and the GH/IGF-I Axis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01150955
Enrollment
24
Registered
2010-06-25
Start date
2010-10-31
Completion date
2011-11-30
Last updated
2012-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Obesity

Keywords

Resveratrol, Diabetes, SIRT1, STAT5, IGF-I, Growth hormone, NAFLD, Longevity, Substrate metabolism, Calorie restriction

Brief summary

We want to investigate whether the food supplement resveratrol is able to counteract the detrimental effects of obesity.

Detailed description

The aim of this study is to investigate potential metabolic effects of resveratrol in healthy but obese men. We hypothesize that resveratrol will counteract some of the detrimental effects of obesity, and as an imitator of calorie restriction will give new insight into the basic biochemical pathways underpinning human metabolism. Of special interest is the potential connection between resveratrol, calorie restriction, SIRT1, STAT5b and the GH/IGF-I axis.

Interventions

DIETARY_SUPPLEMENTResveratrol

500 mg three times a day for five weeks.

OTHERPlacebo

Placebo (starch capsules) 500 mg three times a day for five weeks.

Sponsors

The Ministry of Science, Technology and Innovation, Denmark
CollaboratorOTHER_GOV
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* BMI \> 30 kg/m2 * Otherwise healthy * Written informed consent

Exclusion criteria

* Any disease * Alcohol dependency * Allergy to trial medication * Present or previous malignancy * Participation in other clinical trials within three months before randomization

Design outcomes

Primary

MeasureTime frameDescription
Metabolic parametersFive weeksRegarding glucose, protein and fat metabolism.

Secondary

MeasureTime frameDescription
Pathways of substrate metabolism.Five weeksDescription of the biochemical pathways underpinning the interplay between calorie restriction, SIRT1, STAT5 and the GH/IGF-I axis.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026